Guerbet Logo

Guerbet

ISIN: FR0000032526 | Ticker: GBT | LEI: 969500WV1U1WQ059L135
Sector: Health CareSub-Industry: Pharmaceuticals
Country: France

About Guerbet

Company Description

At Guerbet, we build lasting relationships so that we enable people to live better. This is our Purpose. We place human cooperation at the heart of our relationships and actions.

We are a leader in medical imaging worldwide, offering a wide range of pharmaceutical products, medical devices, digital and AI solutions for diagnostic and interventional imaging.

A pioneer since 95 years in the field of contrast media, we are a team of over 2,600 people globally, continuously innovating with 10% of revenue dedicated to Research & Development across four centers in France, Israel and the United States.

Year founded

1926

Served area

Worldwide

Headcount

2,730

Headquarters

Zone Paris Nord II 15 Rue des Vanesses, 93420 Villepinte – France

Financial statements

Download as Excel
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 945,707,000.00 1,000,833,000.00 939,643,000.00
Noncurrent Assets N/A 477,147,000.00 505,379,000.00 429,970,000.00
Property Plant And Equipment N/A 261,294,000.00 274,046,000.00 286,119,000.00
Intangible Assets Other Than Goodwill N/A 188,267,000.00 188,618,000.00 N/A
Deferred Tax Assets N/A 11,046,000.00 19,419,000.00 16,653,000.00
Other Noncurrent Financial Assets N/A 16,540,000.00 23,295,000.00 29,273,000.00
Current Assets N/A 468,559,000.00 495,454,000.00 509,673,000.00
Inventories N/A 204,587,000.00 201,952,000.00 272,496,000.00
Other Current Financial Assets N/A 56,220,000.00 59,000,000.00 63,955,000.00
Cash and cash equivalents N/A 96,713,000.00 115,728,000.00 41,683,000.00
Noncurrent Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners N/A N/A 0.00 10,300,000.00
Equity And Liabilities N/A 945,707,000.00 1,000,833,000.00 939,643,000.00
Equity 389,192,000.00 367,754,000.00 405,092,000.00 379,570,000.00
Issued Capital N/A 12,603,000.00 12,641,000.00 12,641,000.00
Retained Earnings Profit Loss For Reporting Period N/A N/A 32,637,000.00 -41,116,000.00
Other Reserves N/A 397,461,000.00 408,234,000.00 444,835,000.00
Equity Attributable To Owners Of Parent N/A 364,305,000.00 405,092,000.00 379,570,000.00
Noncurrent Liabilities N/A 377,736,000.00 358,873,000.00 320,453,000.00
Noncurrent Provisions N/A 40,289,000.00 41,988,000.00 32,150,000.00
Deferred Tax Liabilities N/A 14,766,000.00 15,246,000.00 9,872,000.00
Other Noncurrent Financial Liabilities N/A 4,305,000.00 1,947,000.00 0.00
Current Liabilities N/A 200,216,000.00 236,869,000.00 239,620,000.00
Other Shortterm Provisions N/A N/A 9,774,000.00 13,912,000.00
Trade And Other Current Payables N/A 64,413,000.00 81,021,000.00 103,711,000.00
Current Tax Liabilities Current N/A 8,086,000.00 15,011,000.00 19,366,000.00
Liabilities Included In Disposal Groups Classified As Held For Sale N/A N/A 0.00 0.00
Other Current Liabilities N/A 88,438,000.00 97,217,000.00 69,021,000.00
Line item in (eur) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 712,295,000.00 732,071,000.00 753,275,000.00
Revenue From Royalties 0.00 0.00 8,001,000.00
Interest Income On Cash And Cash Equivalents 83,000.00 59,000.00 34,000.00
Other Income 5,397,000.00 4,941,000.00 8,879,000.00
Raw Materials And Consumables Used 166,552,000.00 190,934,000.00 180,424,000.00
Services Expense 203,975,000.00 195,565,000.00 232,585,000.00
Employee Benefits Expense 236,500,000.00 232,789,000.00 240,664,000.00
Depreciation And Amortisation Expense 59,649,000.00 55,945,000.00 119,625,000.00
Tax Expense Other Than Income Tax Expense 15,852,000.00 13,459,000.00 14,992,000.00
Profit Loss From Operating Activities 41,872,000.00 38,685,000.00 -18,160,000.00
Income Tax Expense Continuing Operations 4,008,000.00 -3,664,000.00 12,744,000.00
Profit (loss) 18,240,000.00 32,637,000.00 -41,116,000.00
Profit Loss Attributable To Owners Of Parent 18,240,000.00 32,637,000.00 -41,116,000.00
Line item in (eur) 01.01.2021 01.01.2022 01.01.2023
Profit (loss) 18,240,000.00 32,637,000.00 -41,116,000.00
Adjustments For Income Tax Expense 4,008,000.00 -3,664,000.00 12,744,000.00
Adjustments For Decrease Increase In Inventories 17,383,000.00 4,578,000.00 -68,228,000.00
Adjustments For Depreciation And Amortisation Expense 57,741,000.00 58,320,000.00 123,134,000.00
Adjustments For Provisions 1,379,000.00 8,316,000.00 382,000.00
Adjustments For Sharebased Payments -1,307,000.00 610,000.00 -399,000.00
Adjustments For Fair Value Gains Losses -168,000.00 443,000.00 -1,358,000.00
Adjustments For Losses Gains On Disposal Of Noncurrent Assets 5,367,000.00 286,000.00 2,273,000.00
Cash Flows From Used In Operating Activities 120,432,000.00 115,973,000.00 30,441,000.00
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities 1,644,000.00 840,000.00 1,194,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities 39,792,000.00 37,500,000.00 43,835,000.00
Proceeds From Sales Of Intangible Assets Classified As Investing Activities 1,038,000.00 720,000.00 720,000.00
Purchase Of Intangible Assets Classified As Investing Activities 19,890,000.00 11,431,000.00 6,688,000.00
Cash Flows From Used In Investing Activities -57,288,000.00 -52,243,000.00 -55,398,000.00
Proceeds From Issuing Shares 100,000.00 592,000.00 0.00
Proceeds From Borrowings Classified As Financing Activities 7,337,000.00 6,581,000.00 2,398,000.00
Repayments Of Borrowings Classified As Financing Activities 40,607,000.00 34,392,000.00 35,659,000.00
Dividends Paid Classified As Financing Activities 8,825,000.00 8,814,000.00 10,733,000.00
Interest Paid Classified As Financing Activities 4,890,000.00 5,250,000.00 4,552,000.00
Cash Flows From Used In Financing Activities -46,887,000.00 -41,283,000.00 -48,546,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents -3,699,000.00 68,000.00 -620,000.00
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes 12,560,000.00 22,515,000.00 -74,122,000.00
Cash and cash equivalents 96,713,000.00 115,728,000.00 41,683,000.00

Please note that some sums might not add up.

Filings & Publications

2022

Report
Q1
H1
Q3
FY
Consolidated Report
FRA
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2021

Report
Q1
H1
Q3
FY
Consolidated Report
FRA
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Date Trading entity / Person Association Trade type Volume
03.11.23 None Other Buy EUR 17.92
30.10.23 None Other Buy EUR 17,000.00
25.10.23 None Other Buy EUR 16,800.00
24.10.23 None Other Buy EUR 16,460.90
04.05.23 None Other Buy EUR 4,938.00

Capital markets information

ISIN

FR0000032526

LEI

969500WV1U1WQ059L135

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Sub-Industry

Pharmaceuticals

Listed Stock Exchange

Euronext Paris

Main Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.